Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/33603
Title: | Brazilian multicenter study on pegvisomant treatment in acromegaly |
Authors: | BOGUSZEWSKI, Cesar L.; HUAYLLAS, Martha Katherine P.; VILAR, Lucio; NAVES, Luciana Ansaneli; RIBEIRO-OLIVEIRA JUNIOR, Antonio; SOARES, Beatriz Santana; CZEPIELEWSKI, Mauro Antonio; ABUCHAM, Julio; CORREA-SILVA, Silvia Regina; BRONSTEIN, Marcello Delano; JALLAD, Raquel Soares; DUARTE, Felipe Gaia; MUSOLINO, Nina Rosa; KASUKI, Leandro; GADELHA, Monica Roberto |
Citation: | ARCHIVES OF ENDOCRINOLOGY METABOLISM, v.63, n.4, p.328-336, 2019 |
Abstract: | Objective: Investigate the therapeutic response of acromegaly patients to pegvisomant (PEGV) in a real-life, Brazilian multicenter study. Subjects and methods: Characteristics of acromegaly patients treated with PEGV were reviewed at diagnosis, just before and during treatment. All patients with at least two IGF-I measurements on PEGV were included. Efficacy was defined as any normal IGF-I measurement during treatment. Safety data were reviewed. Predictors of response were determined by comparing controlled versus uncontrolled patients. Results: 109 patients [61 women; median age at diagnosis 34 years; 95.3% macroadenomas] from 10 Brazilian centers were studied. Previous treatment included surgery (89%), radiotherapy (34%), somatostatin receptor ligands (99%), and cabergoline (67%). Before PEGV, median levels of GH, IGF-I and IGF-I % of upper limit of normal were 4.3 mu g/L, 613 ng/mL, and 209%, respectively. Pre-diabetes/diabetes was present in 48.6% and tumor remnant in 71% of patients. Initial dose was 10 mg/day in all except 4 cases, maximum dose was 30 mg/day, and median exposure time was 30.5 months. PEGV was used as monotherapy in 11% of cases. Normal IGF-I levels was obtained in 74.1% of patients. Glycemic control improved in 56.6% of patients with pre-diabetes/diabetes. Exposure time, pre-treatment GH and IGF-I levels were predictors of response. Tumor enlargement occurred in 6.5% and elevation of liver enzymes in 9.2%. PEGV was discontinued in 6 patients and 3 deaths unrelated to the drug were reported. Conclusions: In a real-life scenario, PEGV is a highly effective and safe treatment for acromegaly patients not controlled with other therapies. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - HC/IPq Artigos e Materiais de Revistas Científicas - LIM/25 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_BOGUSZEWSKI_Brazilian_multicenter_study_on_pegvisomant_treatment_in_acromegaly_2019.PDF | publishedVersion (English) | 196.85 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.